Abstract 274P
Background
B-cell lymphoma is associated with an aggressive clinical course, is prone to rapid growth and early progression. Studying gene expression profiles to identify molecular subgroups of lymphomas is a topical issue of haematology as it allows a personalized approach to treatment with high-dose polychemotherapy (PCT) regime with a monoclonal antibody. Such approach improves the immediate treatment efficacy and event-free survival rate. Purpose of the study was to increase the efficacy of therapy in patients with non-Hodgkin large B-cell lymphoma based on the examination of molecular genetic features of the tumor and the use of polychemotherapy based on mutational gene expression profile.
Methods
In this single-center prospective study, 44 patients with non-Hodgkin large B-cell lymphomas stages II-IV A & B were treated at the Department of Hemoblastosis at Kazakh Institute of Oncology and Radiology. Patients with mutated c-MYC gene were treated by high-dose PCT with R+HyperCVAD and we have analysed the treatment outcome.
Results
The FISH test revealed a mutation of c-MYC gene in non-Hodgkin large B-cell lymphoma patients. Therefore, these cases were classified as highly malignant and required high-dose PCT with a monoclonal antibody Rituximab followed by stem cell autotransplantation. This regime of PCT has improved the immediate efficacy of treatment. The patients (18 men and 26 women) were aged 27 to 58 years, with an average age of 42 years. B-cell lymphoma was confirmed in all cases; the complete response amounted to 80.0%; the disease-free survival (DFS) was 18 months (95% CI, 6.592-25.762, P = 0.003).
Conclusions
High-dose PCT in the R+HyperCVAD regimen (3-4 courses) followed by immunotherapy and autotransplantation of hemopoietic stem cells in patients with non-Hodgkin B-cell lymphoma have improved the immediate efficacy and long-term results of treatment of B-cell non-Hodgkin lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Kazakh Institute of Oncology and Radiology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract